PET with the 89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models

Journal of Nuclear Medicine

Jan W. Hesselink¹  Richard C. Gregory¹  Marjolijn N. Lub-de Hooge¹  Marlous E.A. Arjaans¹  Hetty Timmer-Bosscha¹  Thijs H. Oude Munnink¹  Silke R. Vedelaar¹  Annemiek M.E. Walenkamp¹  Carolina P. Schröder¹  Elisabeth G.E. de Vries¹  Michael Reiss¹ 

关键词: transforming growth factor-β;    fresolimumab;    positron emission tomography;    ⁸⁹Zr;   

DOI  :  10.2967/jnumed.111.092809

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Transforming growth factor-β (TGF-β) promotes cancer invasion and metastasis and is therefore a potential drug target for cancer treatment. Fresolimumab, which neutralizes all mammalian active isoforms of TGF-β, was radiolabeled with 89Zr for PET to analyze TGF-β expression, antibody tumor uptake, and organ distribution. Methods: 89Zr was conjugated to fresolimumab using the chelator N-succinyldesferrioxamine-B-tetrafluorphenol. 89Zr-fresolimumab was analyzed for conjugation ratio, aggregation, radiochemical purity, stability, and immunoreactivity. 89Zr-fresolimumab tumor uptake and organ distribution were assessed using 3 protein doses (10, 50, and 100 μg) and compared with 111In-IgG in a human TGF-β–transfected Chinese hamster ovary xenograft model, human breast cancer MDA-MB-231 xenograft, and metastatic model. Latent and active TGF-β1 expression was analyzed in tissue homogenates with enzyme-linked immunosorbent assay. Results: 89Zr was labeled to fresolimumab with high specific activity (>1 GBq/mg), high yield, and high purity. In vitro validation of 89Zr-fresolimumab showed a fully preserved immunoreactivity and long (>1 wk) stability in solution and in human serum. In vivo validation showed an 89Zr-fresolimumab distribution similar to IgG in most organs, except for a higher uptake in the liver in all mice and higher kidney uptake in the 10-μg group. 89Zr-fresolimumab induced no toxicity in mice; it accumulated in primary tumors and metastases in a manner similar to IgG. Both latent and active TGF-β was detected in tumor homogenates, whereas only latent TGF-β could be detected in liver homogenates. Remarkably high 89Zr-fresolimumab uptake was seen in sites of tumor ulceration and in scar tissue, processes in which TGF-β is known to be highly active. Conclusion: Fresolimumab tumor uptake and organ distribution can be visualized and quantified with 89Zr-fresolimumab PET. This technique will be used to guide further clinical development of fresolimumab and could possibly identify patients most likely to benefit.

【 授权许可】

Unknown